Accuray Incorporated (ARAY) - Total Liabilities

Latest as of March 2026: $405.89 Million USD

Based on the latest financial reports, Accuray Incorporated (ARAY) has total liabilities worth $405.89 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ARAY year-over-year net asset growth to track the company's year-over-year net asset growth rate.

Accuray Incorporated - Total Liabilities Trend (2002–2025)

This chart illustrates how Accuray Incorporated's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Accuray Incorporated to measure how efficiently the company converts operating cash flow to free cash.

Accuray Incorporated Competitors by Total Liabilities

The table below lists competitors of Accuray Incorporated ranked by their total liabilities.

Company Country Total Liabilities
Gadang Holdings Bhd
KLSE:9261
Malaysia RM472.27 Million
Ecoplastic Corporation
KQ:038110
Korea ₩1.42 Trillion
Shanghai Material Trading Co Ltd B
SHG:900927
China $463.81 Million
Asia Brands Bhd
KLSE:7722
Malaysia RM58.27 Million
K Way Information
TWO:5201
Taiwan NT$264.47 Million
NATUZZI S.P.A. ADR/5 EO 1
F:NTZA
Germany €248.90 Million
Ibase Gaming
TWO:6441
Taiwan NT$588.10 Million
Shanghai Kai Kai Industry Co Ltd B
SHG:900943
China $878.36 Million

Liability Composition Analysis (2002–2025)

This chart breaks down Accuray Incorporated's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Accuray Incorporated.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.42 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 9.73 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.91 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Accuray Incorporated's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Accuray Incorporated (2002–2025)

The table below shows the annual total liabilities of Accuray Incorporated from 2002 to 2025.

Year Total Liabilities Change
2025-06-30 $389.07 Million -8.14%
2024-06-30 $423.54 Million -0.47%
2023-06-30 $425.56 Million +1.40%
2022-06-30 $419.66 Million +2.04%
2021-06-30 $411.26 Million -3.75%
2020-06-30 $427.29 Million +10.04%
2019-06-30 $388.31 Million +17.64%
2018-06-30 $330.10 Million -8.29%
2017-06-30 $359.93 Million -12.08%
2016-06-30 $409.37 Million +3.85%
2015-06-30 $394.19 Million -0.62%
2014-06-30 $396.64 Million +7.46%
2013-06-30 $369.09 Million +37.06%
2012-06-30 $269.30 Million +24.99%
2011-06-30 $215.46 Million +131.41%
2010-06-30 $93.11 Million -22.72%
2009-06-30 $120.48 Million -26.64%
2008-06-30 $164.24 Million -20.53%
2007-06-30 $206.67 Million -5.84%
2006-06-30 $219.48 Million +53.45%
2005-06-30 $143.03 Million +118.72%
2003-06-30 $65.39 Million +83.92%
2002-06-30 $35.56 Million --

About Accuray Incorporated

NASDAQ:ARAY USA Medical Devices
Market Cap
$32.12 Million
Market Cap Rank
#23465 Global
#5048 in USA
Share Price
$0.27
Change (1 day)
-5.26%
52-Week Range
$0.23 - $1.85
All Time High
$7.46
About

Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation t… Read more